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Head and neck sarcomas are a rare and heterogeneous group of tumors that pose
management challenges. We report our experience with these tumors. Forty consecutive
patients treated for 44 head and neck sarcomas between 1997 and 2014were culled from
our prospectively maintained head and neck database. Five patients were excluded. The
adult cohort consisted 29 (83%) patients of a mean age of 57.7 years, with 33 sarcomas.
The most common diagnoses were undifferentiated pleomorphic sarcoma (27%) and
chondroblastic osteosarcoma (21%). Clear surgical margins were achieved in 24/33
(73%) lesions. Twenty-two patients received radiotherapy and/or chemotherapy. Fourteen
patients developed local (n=6), regional (n=1) and distant (n=7) recurrence. The overall
5-year survival was 66%with a mean survival interval of 66.5months. Recurrent sarcoma,
close (<1mm) or involved surgical margins and advanced age were associated with
statistically significantly reduced survival. The pediatric cohort consisted 6 (17%) patients,
with a mean age of 9 years. Five patients had primary embryonal rhabdomyosarcomas
and one had chondroblastic osteosarcoma. Clear surgical margins were achieved in five
(83%) patients. All patients received adjuvant radiotherapy and/or chemotherapy. Mean
survival interval was 102months. Three patients developed local (n=1) or distant (n=2)
recurrence. Twenty-three free and 8 pedicled flaps were performed in 25 patients. Eleven
out of thirty-nine (28%) lesions in 11 patients developed a complication. In conclusion,
head and neck sarcomas are best managed by a multidisciplinary team at a tertiary
head and neck referral center and resection with clear margins is vital for disease
control.
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Introduction
Four to ten percent of soft tissue and bone sarcomas in adults affect the head and neck region
and account for 1–2% of all head and neck cancer (1–4). Head and neck sarcomas are a hetero-
geneous group of mesenchymal tumors of different histological subtypes. The complex anatomy
of the head and neck region makes these tumors challenging to manage, particularly the need for
multi-modality treatment and consideration for functional, esthetic, quality of life, and survival
outcomes (5). Surgery remains the mainstay treatment for head and neck sarcomas, and histological
subtype becomes a less critical determinant for survival than the operability in terms of anatomic
considerations, tumor size, and stage at diagnosis (1).
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As in tumors located elsewhere, positive surgical margins are a
risk factor for treatment failure. However, wide surgical margins
can be difficult to achieve due to the proximity of vital struc-
tures and tumor involvement of multiple closely related tissue
planes. Furthermore, sarcomas tend to extend outside their pseu-
docapsule and invade tissues that may appear uninvolved during
surgery.
This study presents outcomes of the treatment of head and neck
sarcomas in our tertiary head and neck cancer referral center.
Materials and Methods
Consecutive cases of head and neck sarcomas managed in the
Head and Neck and Skull Base Program of the Wellington
Regional Plastic Maxillofacial and Burns Unit between 1997 and
2014 were culled from our prospectively maintained head and
neck database. Institutional ethics approval was obtained for this
study. All patients who presented with a diagnosis of head and
neck sarcoma were included in this study. Patients who declined
treatment, those with tumors that were inoperable, or those did
not undergo surgery as the primary treatment were excluded from
the study. Patient demographics, tumor site, size and histologic
type, types of ablative and reconstructive surgery, surgical com-
plications, surgical margins, adjuvant therapies, local, regional, or
distant recurrence, and overall survival were analyzed.
All patients were staged according to the American Joint Com-
mittee on Cancer guidelines for soft tissue and bone sarcomas
(6, 7) and were managed by the multidisciplinary head and neck
team. All ablative and reconstructive surgery were performed by
plastic and craniomaxillofacial surgeons (STT, CAM, and CD),
with involvement of a neurosurgeon when a transcranial pro-
cedure was required. A neck dissection was performed when
there was clinical and/or radiological evidence of cervical nodal
metastasis and/or tumor resection encroached on the neck, par-
ticularly if recipient vessels in the neck were needed in free flap
reconstruction. All patients were routinely followed up by the
multidisciplinary head and neck team, initially 1month post-
operatively and then 3-month with CT/MRI examination where
indicated, for 5 years or until death.
Patients were divided into a pediatric cohort up to 16 years of
age and an adult cohort >16 years.
Statistical Analysis
Statistical analysis of potential prognostic factors influencing sur-
vival was performed using SPSS v.22 (GraphPad Inc., La Jolla,
CA, USA).
Results
Of the 1,486 head and neck cancer patients, 40 (3%) patients with
44 sarcomas were identified. Five patients were excluded from
further analysis because they declined surgery (n= 3), the tumor
was inoperable (n= 1) and a 10-year-old child referred for recon-
struction of maxillary hypoplasia following primary chemoradio-
therapy for a right cheek rhabdomyosarcoma 7 years earlier. Thus,
29 (83%) adult and 6 (17%) pediatric patients were available for
analysis (Table 1).
TABLE 1 | Patient demographics, tumor characteristics, and treatment
modality.
Characteristic Number (%)
Age
>16 years 29 (83%)
Up to 16 years 6 (17%)
Sex
Female 18 (51:4)
Male 17 (48:6)
Primary tumor 33 (84:6)
Recurrent tumor 6 (15:4)
Head and neck subsite
Skin and soft tissues 21 (53:8)
Facial skeleton 12 (30:8)
Skull base 6 (15:4)
Maximum diameter
5 cm 24 (61:5)
>5 cm 15 (38:5)
Lymph node status
Negative 3 (7:7)
Positive 36 (92:3)
Surgical margins
Clear (>1mm) 25 (64:1)
Close (<1mm) 5 (12:8)
Involved 9 (23:1)
Treatment modality
Surgery alone 12 (30:8)
Surgery+ radiation 12 (30:8)
Surgery+ chemotherapy 7 (17:9)
Surgery+ radiation+ chemotherapy 8 (20:5)
Adult Patients
Patient and Tumor Characteristics
Twenty-five European and 4 Maori adult patients with a mean
age of 57.7 (median, 62; range, 23–92) years and of equal sex
distribution, were treated for 33 sarcomas. One patient with
Li–Fraumeni syndrome accounted for four asynchronous de
novo sarcomas in the head and neck region (8). There were
21 (64%) cases of skin and soft tissue sarcomas of the head
and neck and 12 (36%) sarcomas involved the facial skeleton
(n= 9) and skull base (n= 3). Twenty-seven primary sarcomas
and six recurrent sarcomas arose from the soft tissue (n= 22)
and bone (n= 11), most commonly undifferentiated pleomorphic
sarcoma (UPS) and chondroblastic osteosarcoma (Figure 1). The
mean tumor size was 3.9 (range, 1–10) cm including stage I
(n= 12), stage II (n= 5), stage III (n= 10), and stage IV (n= 6)
disease at diagnosis. Two patients had distant metastases at
presentation.
Surgical resection with curative intent was performed for 31 of
the 33 sarcomas in 27 patients. Neck dissection was performed
in six patients with osteosarcoma and one patient each with
malignant peripheral nerve sheath tumor involving the vagus
nerve, extra-skeletal Ewing’s sarcoma affecting the submandibular
gland, leiomyosarcoma, liposarcoma, and UPS. Two patients were
treated palliatively including one patient with Ewing’s sarcoma of
the leftmaxilla withmultiple lungmetastases, and another with an
8 cm right mandibular osteosarcoma with a past history of stage
IIIC ovarian cancer treated with surgery and chemoradiotherapy.
Clear surgical margins were achieved in 24 (73%) sarcomas in
20 patients and this included close (<1mm) surgical margins in
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FIGURE 1 | Histological types and numbers of head and neck sarcomas. UPS, undifferentiated pleomorphic sarcoma; DFSP, dermatofibrosarcoma
protuberans.
four sarcomas while involved margins occurred in nine sarcomas.
Selective neck dissection (n= 6) and a modified radical neck
dissection (n= 5) were performed in 11 patients. Three of these
patients had nodal involvement confirmed histologically: one case
each for UPS, extra-skeletal Ewing’s sarcoma of submandibular
gland, and osteosarcoma. Post-operatively 11 patients received
radiotherapy alone, 5 received chemoradiotherapy and 6 received
chemotherapy alone. Two patients declined radiotherapy and in
two cases chemotherapy was discontinued due to toxicity.
Treatment Outcomes
Mean follow-up/survival interval was 66.5 (median, 35; range,
10–281) months. Overall 5-year survival was 66% for patients
treated with curative intent. Local (n= 6), regional (n= 1), and
distant (n= 7) recurrence occurred in 14 patients. The median
interval to local recurrence was 14months. Six of the seven
patients with a local or regional recurrence had involved (n= 4)
or close (<1mm, n= 2) surgical margins. Four of these seven
patients with loco-regional recurrence died from distant metasta-
sis subsequently, two are alive and disease-free, and the remaining
patient is alive but with widespread local disease. Overall, 11
(38%) patients died at a median interval of 21months after
treatment. All but one death occurred within 4.5 years, due
to distant metastasis. The two patients treated palliatively died
from distant metastases 15 and 36months following treatment,
respectively.
Recurrent sarcomas were associated with poorer survival than
primary sarcomas (p= 0.01). In addition, close (<1mm) or
involved surgical margins (Fisher’s Exact test df= 28; p< 0.05)
and advanced age (p< 0.05) were associated with reduced sur-
vival. There was no significant difference in survival between
soft tissue and bone sarcomas, nor between the genders. Tumor
size and tumor stage did not show statistical difference, but the
subgroups were too small in numbers for reliable analysis.
Pediatric Patients
Patient and Tumor Characteristics
Therewere six pediatric patientswith six primary sarcomas, with a
mean age of 9 (median, 12; range 3–15) years, of equal sex distribu-
tion. There were five primary soft tissue sarcomas (all embryonal
rhabdomyosarcomas), and one bone sarcoma (chondroblastic
osteosarcoma) involving the skull base and facial skeleton. The
mean tumor size was 6.3 (range 6.0–6.5) cm, stages III (n= 5) or
IV (n= 1) at presentation.
Surgery with curative intent was performed in five patients,
achieving clear surgical margins in all cases including close
(<1mm) margins in one patient. There was an involved surgical
margin in the case treated palliatively, in which the tumor pre-
sented in the right pterygopalatine fossa with intracranial exten-
sion around the brainstem and cavernous sinus. Four patients
received neoadjuvant chemoradiotherapy, one patient received
radiotherapy alone and the remaining patient underwent neoad-
juvant chemotherapy.
Treatment Outcomes
Median follow-up/survival interval was 74 (mean, 102; range,
13–252) months. One patient developed local and two patients
developed distant metastasis, all of whom died within 31months
of treatment. The two patients who died from distant metastasis
had close (<1mm) or involved surgical margins. The case treated
palliatively developed local recurrence 1month following surgery
and died 12months later.
The number of pediatric cases was too small for meaningful
statistical analysis of potential prognostic factors.
Reconstructive Procedures and Surgical
Complications for the Entire Series
Twenty-three free flaps and eight regional flaps were performed
in 25 patients (Table 2). The patient with Li–Fraumeni syn-
drome had five free flaps following resection of four asynchronous
sarcomas. Another patient with an osteosarcoma involving the
mandible also had five free flaps with no flap failure. A free fibular
osseocutaneous flap and a superficial ulnar artery forearm flap
were performed at initial surgery. Histology showed incomplete
margins and a further resection and reconstruction with the con-
tralateral free fibular osseocutaneous flap and superficial ulnar
artery forearm flap was performed. Two additional free flaps were
performed following flap failure for two other patients.
Eleven out of thirty-nine (28%) tumors in 11 patients devel-
oped 16 complications. More than one complication occurred
in four of these patients. Eight patients with major complica-
tions required re-operation and the remainder were managed
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TABLE 2 | 23 Free Flaps and 8 Regional Flaps in 25 Patientsa.
Types of flaps Number
Free flaps 23
Rectus abdominis muscle or myocutaneous flap 6
Deep circumflex iliac artery flap 5
Fibula osteocutaneous flap 4
Lateral arm fasciocutaneous flap 3
Ulnar forearm fasciocutaneous flap 2
Superficial ulnar artery forearm flap 2
Superficial circumflex iliac artery fasciocutaneous flap 1
Regional flaps 8
Scalp transposition flap 3
Cervicofacial flap 2
Temporalis muscle flap 2
Pectoralis major myocutaneous flap 1
aWith 29 sarcomas.
conservatively (Table 3). Three free flaps required a return
to theater because of venous anastomotic thrombosis. Two of
these flaps ultimately failed requiring a second free flap, both
of which were successful. Hence complete flap loss occurred in
8% of the free flaps performed. There were no peri-operative
deaths.
Discussion
We show a 3% incidence of sarcomas among head and neck
cancer cases treated at our center. The rarity and heterogeneity
of histological subtypes affecting different age groups and dif-
ferent anatomic subsites make analysis of treatment outcomes
of head and neck sarcomas challenging. In this study, the adult
cohort consists of many histological subtypes whereas the pedi-
atric group consisted of sarcomas involving the craniofacial skele-
ton, mostly rhabdomyosarcomas. In our series, adult sarcomas
were six times as common as pediatric sarcomas, with UPS
being the most prevalent (27%) subtype in adults, and rhab-
domyosarcoma being themost prevalent subtype in children. This
is in keeping with the recent SEER report on head and neck
sarcoma (9).
Although both terms refer to the same clinical entity, there
is now general agreement for the term malignant fibrous histi-
ocytoma to be replaced with UPS (10). Being a regional plastic
surgery center that also manages skin and soft tissue tumors may
account for the higher proportion of UPS cases in our adult cohort
compared with other series. We did not encounter radiation-
induced sarcoma in our study. The absence of Kaposi sarcoma
cases in our series reflects a low incidence of HIV infection and
AIDS in New Zealand.
Rhabdomyosarcoma is the most common soft tissue sarcoma
affecting patients younger than 20 years and occur most com-
monly (40%) in the head and neck region (11). In our study, bone-
derived sarcomas represents 33% of cases with osteosarcoma
being the most common subtype, followed by Ewing’s sarcoma,
with the facial skeleton being the most common site. There is one
case of extra-skeletal Ewing’s sarcoma involving the submandibu-
lar gland (12). We found no significant difference in survival
between bone and soft tissue sarcomas.
TABLE 3 | Complications in 11 patients.
Complications Number
Majora 10
Neck hematoma 4f
Free flap venous congestionc 3f
CSF leak following failed free flapd 1f
Infected methylmethacrylate 1
Wound dehiscencee 1
Minorb 6
Partial flap necrosis of cervicofacial flap 2
Chyle leak 1
Horner’s syndrome 1
Recurrent submental abscess 1
Neck seroma 1
aRequired re-operation.
bManaged conservatively.
cOne salvaged, two required second free flap.
dResolved with lumbar drain and a second free flap.
eRequired wound debridement and direct closure.
fOne complication each in a patient requiring one single re-operation.
The majority of sarcomas arise de novo with no identifi-
able causative factor. In our series, three patients had an asso-
ciated predisposing condition. One patient had Li–Fraumeni
syndrome, which is characterized by a p53 mutation, result-
ing in loss of tumor suppression. This predisposes the affected
individual to developing soft tissue sarcomas, osteosarcoma,
pre-menopausal breast cancer, brain tumors, and adrenocorti-
cal carcinoma (13). This patient developed two chondroblastic
osteosarcomas, one liposarcoma, and one undifferentiated sar-
coma over an 11-year period (8). The patient underwent curative
resection of these asynchronous tumors and is disease-free during
a 23-year follow-up. Another patient developed a chondroblas-
tic osteosarcoma in the setting of monostotic fibrous dysplasia
of the mandible. This patient underwent curative resection and
is alive during a 9-year follow-up. The third patient with neu-
rofibromatosis type 1 developed a malignant peripheral nerve
sheath tumor arising from the left vagus nerve (14) and pre-
sented with a left vocal cord paralysis and central neck pain.
Ablative surgery was performed and the patient is alive at 10-year
follow-up.
Eighteen percent of adult cases in our series are recurrent sar-
comas, which are associated with a statistically significant worse
survival rate.Most of these caseswere previously treated elsewhere
without a multidisciplinary team involvement. This necessitates
early referral to a tertiary head and neck cancer center for optimal
management (15). Furthermore, the proximity to vital structures,
their rarity and complexity in diagnosis and management of head
and neck sarcomas underscore the need for referral of these
patients to high-volume specialized centers to achieve optimal
outcomes (16, 17).
While surgery remains the mainstay treatment for head and
neck sarcomas, multi-modality treatment should be considered in
all cases. The role of chemotherapy and/or radiotherapy is proven
in rhabdomyosarcoma, Ewing’s sarcoma, and osteosarcoma (18–
21). However, their precise role for many histological subtypes
remains unclear. Rhabdomyosarcomas are chemosensitive and
in most cases radical excision is considered after neoadjuvant
chemoradiation.
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Radiotherapy is often administered when surgery is unfeasible
or in an adjunctive setting, either pre- or post-operatively, espe-
cially in high-grade tumors or in the presence of positive surgical
margins. Earlier studies (3, 4) have shown that clear surgical mar-
gins are highly significant for local control and that the addition
of adjuvant radiotherapy improves survival, over resection alone.
Furthermore, post-operative adjuvant radiotherapy significantly
increases local control over primary radiotherapy alone (60–82
vs. 43–50%, respectively) (22–24). There has been a long-standing
debate regarding the role of pre-operative radiotherapy in the
management of limb sarcomas (25–27) with one randomized
study reporting improved survival at the expense of a greater
risk of wound complications (25). Although theoretically pre-
operative radiotherapy may increase the likelihood of achiev-
ing clear surgical margins in head and neck sarcomas, evidence
remains lacking. Furthermore, significantly higher surgical com-
plication rates following pre-operative radiotherapy have been
demonstrated in patients undergoing treatment for head and neck
cancer (28).
Generalizations about survival outcomes are difficult given
the heterogeneity of the histological subtypes of the sarcomas
affecting different age groups and different anatomical subsites.
However, there are several key observations relating to the surgical
treatment that are critical to the management of head and neck
sarcomas. The ability to obtain clear surgical margins is a key
determinant of disease control. Ablative surgery with clear surgi-
cal margins is usually achievable despite the anatomic constraints
in the head and neck and skull base. Thirty-six of the 39 sarcomas
(92%) were deemed to be operable with a curative intent. We
achieved clear surgical margins in 73% of adult and pediatric
sarcomas and our results confirm the importance of clear surgical
margins on survival (20, 21, 29, 30). However, Zevallos et al.
(31) show that positive surgical margins do not impact negatively
on survival in pediatric patients undergoing surgical resection of
sinonasal sarcomas (73% being rhabdomyosarcomas) following
neoadjuvant chemotherapy.
The extent of invasion, especially intracranially, is a harbinger
of inability to resect the tumor with clear margins. We usu-
ally only consider surgery for rhabdomyosarcoma if clear exci-
sion margins are feasible. Hence, in view of the associated
morbidity and consequent impact on the quality of life we do
not consider debulking surgery to be appropriate if the resid-
ual tumor will inevitably progress (32). In this study, we have
achieved clear surgical margins in all rhabdomyosarcoma cases
that were treated with curative intent, and a mean survival
of 141months. This compares favorably with other studies (9,
11). The patient treated palliatively was initially diagnosed as
a Schwannoma. However, even if it had been a rhabdomyosar-
coma, surgical resection would have been abandoned. Moretti
et al. (33) have shown that involvement of the parameninges
to be a poor prognosticator and orbital invasion to have a
better prognosis, perhaps due to earlier detection and feasi-
bility to achieve a clear surgical margin in the anterior cra-
nial base.
Rahman et al. (34) observe that Ewing’s sarcomas abutting the
infratemporal fossa are particularly challenging from a resection
standpoint. However, a study by Givi et al. (35) demonstrates rea-
sonable long-term survival following resection of infratemporal
fossa tumors. Willers et al. (36) identify direct tumor extension
into neurovascular structures, bones, continuous organs, or skin
as risk factors for distant metastasis and death.
The feasibility of a curative resection often depends on the
surgical morbidity and implications for the patient’s quality of
life with regard to vision, speech, swallowing, and facial esthetics.
We have shown that immediate flap reconstruction constitutes an
important aspect of the surgical treatment of patients with head
and neck sarcomas, many of whom require free flap transfers. Our
8% free flap failure rate is higher than the 6.3%overall institutional
free flap failure rate (37), and is higher compared to a reported 3%
failure rate of 133 free flap reconstructions following resection of
head and neck sarcomas (38).
Our overall complication rate of 28% compares favorably with
a published peri-operative complication rate of 30.1% and a late
recipient site complication rate of 7.5% (38). Pre-operative radio-
therapy in selected cases may be associated with fewer long-term
complications and no effect on peri-operative complication rate
(26, 27, 39).
Our 66% 5-year overall survival in adult sarcoma cases com-
pares favorably with 44–70% reported in other series (3, 4, 9, 23,
24, 30, 36, 40–42). Long-term survival is likely with a follow-up
of around 4.5 years being the critical landmark. All the deaths,
except one, occurred before this time point. Advanced age is a sig-
nificant risk factor for worse survival. Deaths usually results from
hematogenous metastasis, usually to the lungs, brain, and bones
(4, 36, 40). All deaths in our series resulted from pulmonary or
visceral metastasis.We have previously shown that 3 of 11 patients
with head and neck UPS presented with cervical metastasis (43).
However, in this study, only one case of UPS had lymph node
involvement confirmed histologically, and overall, three adult
cases (9%) had lymph node involvement in comparison to 3%
incidence reported by Brentz et al. (40).
Conclusion
Head and neck sarcomas are a heterogenous group of tumors
that pose significant management challenges.We have shown that
surgical resection with clear margins is critical for survival and
immediate reconstruction is an integral part of the surgical treat-
ment. The high rate of surgical complications reflects the com-
plexity of the clinical problem. Treatment of these tumors should
be provided by multidisciplinary teams at specialized centers to
achieve optimal outcomes.
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